PRAX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRAX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.
As of today, Praxis Precision Medicines's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.
For the Biotechnology subindustry, Praxis Precision Medicines's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:
* The bar in red indicates where Praxis Precision Medicines's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.
Praxis Precision Medicines (NAS:PRAX) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation
Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.
In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.
Thank you for viewing the detailed overview of Praxis Precision Medicines's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.
Jill Desimone | director | C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110 |
Marcio Souza | officer: Chief Executive Officer | C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
Dean J Mitchell | director | C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164 |
Timothy Edwin Kelly | officer: Chief Financial Officer | C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
Lauren Mastrocola | officer: Principal Accounting Officer | C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
Alex Nemiroff | officer: General Counsel and Secretary | C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
Bsof Parallel Master Fund L.p. | 10 percent owner | 345 PARK AVENUE, NEW YORK NY 10154 |
Merit Ester Cudkowicz | director | C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
Jeffrey Chodakewitz | director | C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL ST., SUITE 101, WATERTOWN MA 02472 |
Stefan Vitorovic | director | C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
Blackstone Holdings I/ii Gp L.l.c. | 10 percent owner | C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154 |
William D Young | director | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Stephen A Schwarzman | 10 percent owner | C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154 |
Blackstone Inc. | 10 percent owner | 345 PARK AVENUE, NEW YORK NY 10154 |
Blackstone Group Management L.l.c. | 10 percent owner | C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154 |
From GuruFocus
By PurpleRose PurpleRose • 08-03-2022
By Marketwired • 06-22-2023
By Marketwired • 11-07-2023
By Marketwired • 08-31-2023
By Value_Insider Value_Insider • 11-28-2022
By sperokesalga sperokesalga • 06-09-2023
By Marketwired • 10-02-2023
By sperokesalga sperokesalga • 06-15-2023
By Value_Insider Value_Insider • 11-07-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.